Needle or Drip?-Real-World Comparison of Intravenous to Subcutaneous Infliximab and Vedolizumab in the Management of Inflammatory Bowel Diseases

Dig Dis Sci. 2024 Dec 4. doi: 10.1007/s10620-024-08772-4. Online ahead of print.
No abstract available

Publication types

  • Editorial